{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06414889",
            "orgStudyIdInfo": {
                "id": "2023-0799"
            },
            "secondaryIdInfos": [
                {
                    "id": "NCI-2024-04300",
                    "type": "OTHER",
                    "domain": "NCI-CTRP Clinical Registry"
                }
            ],
            "organization": {
                "fullName": "M.D. Anderson Cancer Center",
                "class": "OTHER"
            },
            "briefTitle": "Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder",
            "officialTitle": "Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder",
            "therapeuticArea": [
                "Other"
            ],
            "study": "protocol-title-safety-and-feasibility-of-autologous-hematopoietic-stem-cells-mobilization-and-apheresis-in-participants-with-familial-platelet-disorder"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-05-20",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-06-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-06-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-05-10",
            "studyFirstSubmitQcDate": "2024-05-10",
            "studyFirstPostDateStruct": {
                "date": "2024-05-16",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-21",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-22",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "M.D. Anderson Cancer Center",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "RUNX1 Foundation",
                    "class": "UNKNOWN"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "To evaluate the safety and feasibility of collecting hematopoietic stem cells (HSC) in participants with RUNX1-FPD.",
            "detailedDescription": "Primary Objective:\n\n- To evaluate the safety of harvesting HSCs in participants with RUNX1 FPD\n\nSecondary Objective\n\n- To evaluate the feasibility and other relevant information of collecting HSCs from participants with RUNX1 FPD"
        },
        "conditionsModule": {
            "conditions": [
                "RUNX1 Familial Platelet Disorder"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "EARLY_PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "OTHER",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 4,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis",
                    "type": "EXPERIMENTAL",
                    "description": "On Days 1-5, participants will receive a Granulocyte colony-stimulating factor (G-CSF), such as filgrastim, as an injection or by vein over about 5 minutes.\n\nIf the study doctor thinks it is needed, participants will also receive plerixafor as an injection under the skin on Day 5 (and 6, if you have 2 days of apheresis).",
                    "interventionNames": [
                        "Drug: G-CSF (filgrastim or biosimilar)",
                        "Procedure: Apheresis",
                        "Drug: Plerixafor"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "G-CSF (filgrastim or biosimilar)",
                    "description": "Given by IV or SC",
                    "armGroupLabels": [
                        "Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis"
                    ],
                    "otherNames": [
                        "FILGRASTIM SD/01"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "Apheresis",
                    "description": "Given by procedure",
                    "armGroupLabels": [
                        "Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Plerixafor",
                    "description": "Given by IV",
                    "armGroupLabels": [
                        "Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Safety and adverse events (AEs)",
                    "description": "Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",
                    "timeFrame": "Through study completion; an average of 1 year."
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nParticipants who meet all of the following criteria are eligible to be included in the study:\n\n1. Are aged \u2265 18 to 75 years\n\n   a. Once a favorable review of safety has been completed by the SMC in 3 participants aged \u2265 18 years, the study will be opened to participants aged \u2265 12 years.\n2. Are willing and able to provide informed consent, as appropriate (either directly or through a legally authorized representative \\[LAR\\]), as described in Appendix 1, Section 13.1\n3. Have a confirmed diagnosis of RUNX1 FPD, verified by a Clinical Laboratory Improvement Amendments (CLIA)-certified genetic sequencing report.\n4. Clearance by apheresis team to proceed\n5. Have systolic blood pressure \u2264 170 mm Hg and diastolic blood pressure \u2264 95 mmHg\n6. Are eligible for HSCT per institution requirements\n7. Have a Lansky (age \\< 16 years)/Karnofsky performance status of \u2265 70 (see Appendix 2, Section 13.2).\n8. Are willing and able to comply with protocol-defined contraceptive requirements (see Appendix 3 Section 13.3)\n9. Have a platelet count \u2265 50,000/\u03bcL for initiation of apheresis, assessed within 24 hours prior to the procedure, or, if \\< 50,000/\u03bcL are administered platelets on the day of the collection\n\n   a. If the apheresis team decides that a central venous catheter (CVC) is to be placed, platelet count should be \u2265 50,000 prior to catheter placement.\n10. Have hemoglobin \u2265 7.5 g/dL as assessed within 24 hours prior to the procedure\n\nExclusion Criteria:\n\nParticipants who meet any of the following criteria are excluded from the study:\n\n1. Participants with cognitive impairments and/or any serious unstable pre-existing medical condition or psychiatric disorder that can interfere with safety or with obtaining informed consent or compliance with study procedures.\n2. Have uncontrolled bleeding\n3. Are using supplemental oxygen\n4. Have known severe splenomegaly (\u2265 20 cm)\n5. Have a diagnosis of MDS or hematologic malignancies, as defined by WHO hematolymphoid tumor classification fifth edition (Khourey et al 2022) hematolymphoid tumor classification fifth edition (Khourey et al 2022)\n6. Have recent prior malignancies except resected basal cell carcinoma or treated cervical carcinoma in situ Note: Cancer treated with curative intent \\< 5 years previously may be allowed following approval from the study investigator. Cancer treated with curative intent \\> 5 years previously is allowed.\n7. Have any prior or current myeloproliferative or a significant coagulation or immunodeficiency disorder\n8. Have advanced liver disease, defined as any of the following:\n\n   1. Persistent aspartate transaminase, alanine transaminase, or direct bilirubin value \\> 5\u00d7 the upper limit of normal (ULN) at screening\n   2. Screening prothrombin time (PT) or partial thromboplastin time (PTT) \\> 1.5\u00d7 ULN\n9. Have had prior HSCT or gene therapy\n10. Have history of concomitant sickle cell disease\n11. Have been treated with an investigational drug within 30 days of screening or 5 half-lives (whichever is longer)\n12. Have a positive test result for HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV) at screening\n\n    1. Participants with positive hepatitis B core antibody (HbcAb) and/or hepatitis B-e antibody (HbeAb) are eligible provided viral load is negative by quantitative polymerase chain reaction (qPCR).\n    2. Participants who are positive for anti-hepatitis C antibody are eligible as long as they have a negative HCV viral load by qPCR.\n13. Have a positive infectious disease panel at screening for human T-lymphotropic virus 1 or 2 (HTLV-1 and HTLV-2), or syphilis (rapid plasma 24 reagin \\[RPR\\])\n14. Have clinically significant and active bacterial, viral, fungal, or parasitic infection at screening\n15. Have a white blood cell (WBC) count \\< 2 \u00d7 109/L\n16. Have a left ventricular ejection fraction \\< 45%\n17. Have a screening estimated glomerular filtration rate \\< 60 mL/min/1.73 m2\n18. Have a diagnosis of a significant psychiatric disorder that could seriously impede the ability to participate in the study\n19. For women of childbearing potential: are pregnant or breastfeeding or lack adequate contraception\n20. Are unable to comply with the study procedures, as assessed by the investigator",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "75 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Chitra Hosing, MD",
                    "role": "CONTACT",
                    "phone": "(713) 745-3219",
                    "email": "cmhosing@mdanderson.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Chitra Hosing",
                    "affiliation": "M.D. Anderson Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Chitra Hosing, MD",
                            "role": "CONTACT",
                            "phone": "713-745-3219",
                            "email": "cmhosing@mdanderson.org"
                        },
                        {
                            "name": "Chitra Hosing, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "MD Anderson Cancer Center",
                    "url": "http://www.mdanderson.org"
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001791",
                    "term": "Blood Platelet Disorders"
                }
            ],
            "ancestors": [
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5072",
                    "name": "Blood Platelet Disorders",
                    "asFound": "Platelet Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000088327",
                    "term": "Plerixafor"
                },
                {
                    "id": "D000078224",
                    "term": "Lenograstim"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000276",
                    "term": "Adjuvants, Immunologic"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000019380",
                    "term": "Anti-HIV Agents"
                },
                {
                    "id": "D000044966",
                    "term": "Anti-Retroviral Agents"
                },
                {
                    "id": "D000000998",
                    "term": "Antiviral Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M1945",
                    "name": "Lenograstim",
                    "asFound": "Site",
                    "relevance": "HIGH"
                },
                {
                    "id": "M340828",
                    "name": "Plerixafor",
                    "asFound": "Same as",
                    "relevance": "HIGH"
                },
                {
                    "id": "M3628",
                    "name": "Adjuvants, Immunologic",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M21350",
                    "name": "Anti-HIV Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M25428",
                    "name": "Anti-Retroviral Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4314",
                    "name": "Antiviral Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                }
            ]
        }
    },
    "hasResults": false
}